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Abstract 
Background: Kallikrein 9 (KLK9) is a member of the human kallikrein-related peptidases family, whose physiological 
role and implications in disease processes remain unclear. The active form of the enzyme is predicted to have chymo-
tryptic activity. In the present study, we produced for the first time the active recombinant protein and monoclonal 
antibodies, and developed novel immunoassays for the quantification of free and bound KLK9 in biological samples.
Methods: The coding sequence of mature KLK9 isoform (mat-KLK9) was expressed in an Expi293F mammalian 
system and the synthesized polypeptide was purified through a two-step protocol. The purified protein was used as 
an immunogen for production of monoclonal antibodies in mice. Hybridomas were further expanded and antibodies 
were purified. Newly-produced monoclonal antibodies were screened for reaction with the KLK9 recombinant protein 
by a state-of-the-art immunocapture/parallel reaction monitoring mass spectrometry-based methodology.
Results: Anti-KLK9 antibodies were combined in pairs, resulting in the development of a highly sensitive (limit of 
detection: 15 pg/mL) and specific (no cross-reactivity with other KLKs) sandwich-type ELISA. Highest KLK9 protein 
levels were found in tonsil and sweat and lower levels in the heart, kidney and liver. Hybrid immunoassays using an 
anti-KLK9 antibody for antigen capture and various anti-serine protease inhibitor polyclonal antibodies, revealed the 
presence of an a1-antichymotrypsin-bound KLK9 isoform in biological samples.
Conclusions: The ELISAs for free and bound forms of KLK9 may be highly useful for the detection of KLK9 in a broad 
range of biological samples, thus enabling the clarification of KLK9 function and use as a potential disease biomarker.
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Background
Human tissue kallikrein-related peptidases (KLKs) con-
stitute the largest family of secreted serine proteases, 
with diverse expression patterns and physiological roles 
[1]. Aberrant KLK activity has been linked to various 
pathologies such as respiratory diseases, neurodegenera-
tion, skin-barrier dysfunction and cancer. Thus, KLKs are 
attractive targets for novel therapeutics [2]. The deregula-
tion of KLKs at the gene and protein level has been asso-
ciated with the hallmarks of cancer [3].
Human tissue kallikrein 9 (KLK9), which was originally 
identified as the KLK-L3 gene, spans an area of 7.1  kb 
on chromosome 19, flanked by the KLK8 and KLK10 
genes [4]. The full gene sequence (GenBank accession no. 
AF135026) contains five coding exons and the encoded 
KLK9 protein (UniProt accession: Q9UKQ9 (KLK9_
HUMAN)) is predicted to be synthesized as a pre-pro-
enzyme (1–250 amino acids) which is processed to the 
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According to previous RNA data, KLK9 was found to 
be expressed in a restricted number of tissues, including 
the salivary gland, ovary [4] esophagus, tonsil and skin 
(http://www.proteinatlas.org/). Some recent data sug-
gest that KLK9 may play an important biological role. In 
brief, the mRNA level of KLK9 expression has favorable 
prognostic value in ovarian [6] and breast cancer [7], 
while elevated KLK9 expression levels were associated 
with higher grade gliomas [8]. Further analysis of cancer 
cell lines revealed that KLK9 is constitutively expressed 
in breast, ovarian and lung cancer [9]. Recent studies 
associate KLK9 expression patterns with non-malignant 
diseases, such as cardiac hypertrophy and hypertension-
induced target organ damage [10] psoriatic lesions [11] 
and complications in asthma patients [12].
Based on the cited literature, we hypothesized that 
KLK9 may be involved in various pathologies and could 
be a disease biomarker of diagnosis/prognosis. These 
studies could benefit from a highly sensitive and specific 
KLK9 ELISA, which was not available until today.
In this study, we describe the production and charac-
terization of mouse monoclonal antibodies against the 
mature KLK9 form (mat-KLK9) and the development of 
a highly sensitive and specific ELISA assay for the free 
monomer. We also developed an ELISA that measures 
the inhibitor-bound KLK9 form, through a hybrid assay 
that includes a1-antichymotrypsin antibodies. These 
assays were used to quantify free and bound forms of 
KLK9 in tissue extracts and biological fluids.
Methods
Production of recombinant KLK9 in the Expi293 transient 
mammalian expression system
The mature form of KLK9 (mat-KLK9) (aa 23–250) was 
expressed in the Expi293 mammalian protein expres-
sion system (ThermoFisher Scientific, Carlsbad, CA, 
USA). The expression plasmid pCDNA3.4, carrying the 
appropriate part of the KLK9 gene (pCDNA3.4-KLK9), 
in-frame with a mammalian IgK-chain secretion signal 
peptide (METDTLLLWVLLLWVPGSTG) was synthe-
sized using Gene Art synthesis under optimal conditions 
(Invitrogen, Carlsbad, CA, USA). The pCDNA3.4-KLK9 
plasmid was amplified via transformation of E. coli One 
Shot™ TOP10 chemically competent cells according to 
the company’s instructions (Invitrogen). The plasmid was 
purified (PureLink™ HiPure Plasmid Midiprep Kit, Invit-
rogen) and the KLK9 sequence was further confirmed by 
DNA sequencing (ACGT Corp. Toronto, Canada).
The mat-KLK9 protein was expressed in suspension 
Expi293 cells according to the manufacturer’s instruc-
tions after optimization. Briefly, for each 30  mL small 
scale KLK9 expression, Expi293F™ cells were diluted 
in Expi293™ Expression medium to a final cell density 
of 3 ×  106 cells/mL in 25.5  mL (125-mL flask). For the 
transfection of the Expi293F™ cells with pCDNA3.4-
KLK9 plasmid: (1) 30 μg of the plasmid were diluted in 
Opti-MEM® I Reduced Serum Medium to a total vol-
ume of 1.5  mL, (2) 90  μL of ExpiFectamine™ 293 Rea-
gent was diluted in Opti-MEM® I medium to a total 
volume of 1.5 mL and incubated for 5 min at room tem-
perature, (3) The diluted DNA was added to the diluted 
ExpiFectamine™ 293 Reagent and the mixture was incu-
bated for 20 min at room temperature, to allow the DNA-
ExpiFectamine™ 293 Reagent complexes to form, (4) The 
3  mL of the DNA-lipid complexes were added to each 
flask and the cells incubated at 37 °C in 8% CO2 air under 
125 rpm shaking, (5) after 24 h incubation, a mixture of 
enhancers (150  μL of ExpiFectamine™ 293 Transfection 
Enhancer 1 and 1.5 mL of ExpiFectamine™ 293 Transfec-
tion Enhancer 2) were added to each flask (final volume: 
30  mL). Media from each flask, containing the secreted 
KLK9 protein, were harvested at different time points 
(24, 48, 72 and 96  h post-transfection) and the KLK9 
protein expression was verified by Western blot analy-
sis using existing in-house KLK9 antibodies. Large scale 
protein expression was followed, and the media was har-
vested at 96  h post-transfection, concentrated 10× and 
stored at −80  °C until use. The yield was estimated by 
mat-KLK9 quantification using selected reaction moni-
toring (SRM) analysis (see below).
Purification of mat‑KLK9
Mat-KLK9 was purified using a two-step purification 
protocol. Initially the KLK9 supernatant was diluted 3 
times with the equilibration buffer (50  mM Tris–HCl, 
pH 9.0) and the protein was purified using the Akta FPLC 
system on a Mono Q™ 4.6/100 PE column (GE Health-
care, Life Sciences, Mississauga, ON, Canada). The con-
ditions of the purification procedure were as follows: 
Equilibration buffer: 50  mM Tris–HCl (pH 9.0), elution 
buffer: 50 mM Tris–HCl (pH 9.0) + 1 M NaCl, flow rate: 
2  mL/min, step-gradient of the elution buffer: 5% for 
10  min, linear gradient: 5–40% for 44  min (fractions of 
4 mL each were collected), step-gradient: 100% for 5 min. 
KLK9 was eluted using linear gradient of elution buffer at 
approximately 200 mM NaCl. To further purify KLK9 to 
homogeneity, reversed-phase HPLC was used as a second 
purification step. KLK9-containing fractions were com-
bined, diluted to 1% (v/v) TFA and loaded onto a Viva 
C4 column (5 μm, 50 × 4.6 mm, Restek, USA). The fol-
lowing multi-step gradient elution (0.1% trifluoroacetic 
acid and 0.1% trifluoroacetic acid in 90% acetonitrile) at a 
flow rate of 1 mL/min was used: linear gradient (10–40% 
acetonitrile for 5 min), 40% acetonitrile for 10 min, linear 
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gradient (40–50% for 20  min), linear gradient (50–80% 
acetonitrile for 5  min), 80% for 5  min and linear gradi-
ent (80–10% acetonitrile for 2 min). KLK9 was eluted at 
approximately 40–50% acetonitrile. The presence and 
the identity of the purified KLK9 in the positive fractions 
(after acetonitrile evaporation) was confirmed by West-
ern blotting and SRM analysis (see below). The protein 
purity was verified by silver and Coomassie-staining.
SDS‑PAGE and Western blotting analyses of KLK9
SDS-PAGE was performed using 4–12% gradient poly-
acrylamide gels at 200  V for 45  min (BIO-RAD). Gels 
were either stained using the silver staining kit (Plu-
sOne Silver staining protein kit, GE Healthcare) or with 
Biosafe Coomassie staining (Invitrogen). For the West-
ern blot analysis, a Trans-Blot Turbo Transfer Starter 
system (BIO-RAD) was used. Briefly, after transfer, the 
PVDF membranes were blocked in 5% milk for 2 h and 
further incubated with the in-house primary anti-KLK9 
mouse monoclonal antibody in 1% milk (1/500 dilution) 
for 2  h. Next, membranes were washed 4 times with 
Tris-buffered saline, 0.1% Tween-20 (TBST) and further 
incubated with peroxidase-conjugated goat anti-mouse 
IgG antibody (1/10,000) for 45 min at room temperature. 
After 4 times washing with TBST, membranes were incu-
bated with ECL Western blotting detection reagents (GE 
Healthcare) and exposed to X-ray film.
Selected reaction monitoring (SRM) analysis of KLK9
Ten µg of total protein were aliquoted from a crude 
KLK9-secreting Expi293 cell culture supernatant, as 
well as from purified fractions. Samples were initially 
mixed with 50  mM ammonium bicarbonate (ABC) and 
10  mM dithiothreitol (DTT). Following the addition of 
a heavy-labeled KLK9 peptide (2500  fmol for the crude 
supernatant and 600 fmol for the purified KLK9, respec-
tively), samples were incubated at 60  °C for 30  min. 
Subsequently, 20  mM iodoacetamide (IAA) were added 
and samples were left in the dark for 1 h at RT. Proteins 
were then digested overnight at 37 °C using trypsin from 
porcine pancreas (Sigma, T6567-5X, USA) at 1:30 ratio 
(trypsin: total protein). Trypsin inactivation was accom-
plished with the addition of TFA at a final concentration 
1% (v/v). Peptides were extracted using C18 Bond Elut 
OMIX tips (Agilent Technologies, Mississauga, ON, Can-
ada) and eluted in 5 µL of 65% acetonitrile in 0.1% formic 
acid. Finally, eluates were further diluted to 60  μL with 
0.1% formic acid. Using a 96-well microplate autosam-
pler on an Eksigent ekspert NanoLC 425 system, 18  μL 
of each sample were loaded onto a 15 cm long 3 μm par-
ticle C18 analytical column (i.d. 75  μm) with an 8  μm 
tip (New Objective, Woburn, MA, USA). The mobile 
phase consisted of 0.1% formic acid in water (buffer A) 
and 0.1% formic acid in acetonitrile (buffer B). Peptides 
were separated with a 22 min gradient elution at a flow 
rate of 350 nL/min. The gradient started with 1% buffer 
B and ramped to 14% buffer B over 1  min, followed by 
an increase to 40% buffer B over the next 11  min. The 
gradient then ramped further to 65% buffer B over 2 min 
before it reached 100% within 1  min and was kept at 
that concentration for 7  min. The nano-pump was cou-
pled online to a 6500 QTRAP 6500 quadrupole-ion trap 
mass spectrometer (AB Sciex, Concord, ON, Canada) 
equipped with a NanoSpray III source and a PhotoSpray 
ionization source. Declustering and entrance potentials 
were set to 150 and 10  V, respectively. Resolutions for 
both the first quadrupole and the ion trap were set to 
“unit” [0.7  Da Full Width at half maximum (FWHM)]. 
In order to exclude possible interferences, to ensure cor-
rect identity of each peak and to achieve absolute quan-
tification of the protein, a heavy isotope-labeled peptide 
internal standard with a quantifying tag was synthesized 
for KLK9 (SpikeTides™_TQL, JPT Peptide Technologies 
GmbH, Berlin, Germany). For the SRM method, 4 tran-
sitions of (+3) precursor ion VTDFFPHPGFNK and its 
heavy-labelled counterpart were monitored (Additional 
file  1: Table S1). For each transition, scan time was set 
to 30  ms, while retention time was 12.1  min. Absolute 
quantification of the recombinant protein was achieved 
by comparing the peak area of the chromatographic peak 
of the endogenous peptide (VTDFFPHPGFNK) to the 
corresponding internal standard in each sample. Results 
were evaluated using the Skyline software (Mac Coss Lab 
Software, Seattle, WA, USA).
Monoclonal antibody production in mice
Female BALB/c mice were purchased from Jackson 
laboratories via the Toronto Centre for Phenogenom-
ics (TCP). All animal research was approved by the TCP 
Animal Care Committee. Mice were injected subcuta-
neously with 100  μg of mat-KLK9 protein, mixed (1:1) 
with Sigma Adjuvant System (Sigma-Aldrich). Two sub-
sequent booster injections with 25 μg of antigen in adju-
vant were performed at 3-week intervals. Final boost 
was an intraperitoneal injection of 25  μg of antigen in 
phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4). Three days later, the 
mouse spleen was excised aseptically and homogenized. 
Extracted spleen cells were fused with NSO murine mye-
loma cells (5:1 ratio) using polyethylene glycol (Sigma-
Aldrich). Successfully fused cells were selected using 
HAT media (Invitrogen), supplemented with 20% fetal 
bovine serum (Hyclone, Thermo-Fisher Scientific, Walt-
man, MA, USA).
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Screening for immunogen‑reacting clones by an IgG 
capture ELISA
White polystyrene 96-well microtiter plates were coated 
with 500  ng/well of sheep anti-mouse IgG, Fcγ frag-
ment-specific antibody (Jackson ImmunoResearch, West 
Grove, PA, USA) in 50  mM Tris buffer (pH 7.8). Plates 
were washed 3 times with 0.05% Tween 20 in 20  mM 
Tris, 150  mM NaCl (pH 7.4). Cell culture supernatants 
of hybridoma cells diluted twofold in a solution contain-
ing 10  g/L BSA in 50  mM Tris (pH 7.8) were added to 
the plates and incubated for 2 h at RT with gentle shak-
ing. Plates were then washed 3 times with the wash-
ing buffer. Five nanograms of biotinylated mat-KLK9 in 
assay diluent were added into each well (100 μL/well) and 
incubated for 2 h at room temperature (RT) with gentle 
shaking. Plates were washed 3 times and alkaline phos-
phatase-conjugated streptavidin was added (100  μL per 
well). Incubation was for 20 min at RT with gentle shak-
ing, followed by a final wash (6 times). Diflunisal phos-
phate (DFP) solution was prepared in substrate buffer 
(0.1 M NaCl, 1 mM MgCl2 in 0.1 M Tris, pH 9.1), added 
to the plate (100 μL per well) and incubated for 10 min 
at RT with gentle shaking. Subsequently, the developing 
solution (1 M Tris, 0.4 M NaOH, 2 mM TbCl3 and 3 mM 
EDTA) was added on top and mixed for 1  min. Time-
resolved fluorescence was measured with the Wallac 
EnVision 2103 Multilabel Reader (Perkin Elmer), as pre-
viously described [13].
Expansion of hybridoma cell cultures and purification 
of anti‑KLK9 monoclonal antibodies
Following the screening procedure, hybridoma cells were 
further grown and transferred in serum-free medium 
(CD-1 medium; Invitrogen), containing 8  mM  l-glu-
tamine. Supernatants were collected and purified using 
a Protein G column, according to the manufacturer’s pro-
tocol (GenScript, Piscataway NJ, USA). Culture super-
natants were diluted two-fold with the binding buffer 
(20 mM NaH2PO4, 150 mM NaCl, pH 8.0) and loaded on 
the column. The column was then washed with the bind-
ing buffer and antibodies were eluted with 0.1 M glycine 
at pH 3.0.
Immunocapture‑PRM screening for purified mouse 
antibodies against KLK9
500  ng of each purified monoclonal antibody were 
diluted in 100  μL of coating buffer (50  mM Tris buffer, 
pH 7.8), added in each well of a 96-well polystyrene 
microtiter plate and incubated overnight at RT. The plate 
was then washed three times with phosphate-buffered 
saline (PBS). The mat-KLK9 antigen (10 or 50  ng) was 
added to each well and was further diluted up to 100 μL 
with 1% (w/v) BSA in PBS buffer. Wells with no KLK9 
antigen added, were used as negative controls. The plate 
was incubated for 2  h at room temperature with gentle 
shaking and was finally washed three times with PBS and 
three times with 50  mM ABC. The captured antigens 
were subsequently subjected to trypin digestion. 88 μL of 
ABC buffer (100 mM), and 10 μL of DTT (50 mM) were 
added in each well and incubated at room temperature 
for 30 min. After reduction, the samples were alkylated in 
the dark at room temperature for 1 h, by adding 10 μL of 
IAA (100 mM). Five hundred femtomoles of KLK9 heavy 
isotope-labeled peptides with a quantitation tag (Spike-
Tides™_TQL, JPT Peptide Technologies GmbH, Berlin, 
Germany) were added to all samples prior to trypsin 
digestion. Each sample was digested overnight by the 
addition of 5  μL of sequencing grade modified trypsin 
(0.05 μg/μL) in 50 mM ABC (trypsin from porcine pan-
creas, Sigma). Trifluoroacetic acid (1%) was finally added 
in each well to stop the reaction. Microextraction and 
desalting of peptides was performed with C18, as previ-
ously described [14].
Tryptic peptides were loaded onto a 3  cm long 5  μm 
particle C18 trap precolumn (i.d. 200 μm) via an EASY-
nLC pump (Proxeon Biosystems, Odense, Denmark) at 
8 μL/min before switching in- line with the gradient. The 
mobile phase consisted of 0.1% of formic acid in water 
(buffer A) and 0.1% of formic acid in acetonitrile (buffer 
B). Peptides were separated on a 15 cm long 3 μm parti-
cle C18 analytical column (i.d. 75 μm) with an 8 μm tip 
(New Objective) with a 22 min gradient elution at a flow 
rate of 350 nL/min. The gradient started with 1% buffer 
B and ramped to 14% buffer B over 1  min, followed by 
an increase to 40% buffer B over the next 11  min. The 
gradient then ramped further to 65% buffer B over 2 min 
before it reached 100% within 1  min and was kept at 
that concentration for 7  min. The EASY-nLC system 
was coupled online to a Q Exactive Plus hybrid quadru-
pole-orbitrap mass spectrometer (Thermo Fisher Sci-
entific, Berlin, Germany). The performance settings for 
the PRM method were the following: in-source collision 
induced dissociation was set to 3.0 eV, MS transitions in 
the orbitrap were acquired with 17,500 resolving power 
at 200 m/z, AGC target was set to 3 × 106 with a maxi-
mum injection time of 100 ms, the isolation window was 
set to 1.0 m/z and the normalized collision energy was set 
to 25. The performance of the nanoLC analytical column 
and the mass spectrometer were verified at the beginning 
of each day, and every six runs thought the day, by the 
analysis of a quality control solution of 1 fmol/μL BSA. 
Two KLK9 proteotypic peptides (WEGPEQLFR and 
LFCGATLISDR) were used for protein identification and 
one peptide (VTDFFPHPGFNK) was used for protein 
quantification. The absolute quantification of the pro-
tein was calculated by taking the area ratios of heavy to 
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light peptides and correlated to the concentration of the 
heavy peptides spiked into each sample. The .raw files of 
PRM runs were recorded for each sample and were ana-
lyzed using Skyline Targeted Proteomics Environment 
v3.1.0.7382  (MacCoss Lab Software, Seattle, WA, USA) 
and the.csv files with peptide areas were extracted.
Development of a fluorometric KLK9 immunoassay
A sandwich type ELISA immunoassay was developed 
using mouse monoclonal antibodies as capture and bioti-
nylated detection antibodies, respectively. White polysty-
rene microtiter plates were coated with 500 ng of mouse 
monoclonal anti-KLK9 antibody diluted in 50  mM 
Tris buffer (pH 7.8). The plate was incubated over-
night at room temperature (RT) and the following day 
was washed 3 times with washing buffer (20  mM Tris, 
150  mM NaCl, 0.05% Tween-20, pH 7.4). KLK9 stand-
ards diluted in 6% BSA or samples were then added into 
each well (50 μL/well) along with 50 μL of assay Buffer A 
(60  g/L BSA, 25  mL/L normal mouse serum, 100  mL/L 
normal goat serum, and 10  g/L bovine IgG in 50  mM 
Tris, pH 7.8, 0.005% (v/v) Tween-20) and incubated for 
2  h with shaking. The plates were washed 3 times and 
100  μL of the detection mouse biotinylated anti-KLK9 
antibody, diluted in Buffer A (0.2 μg/mL) was applied in 
each well and incubated for 1 h. After washing 3 times, 
100  μL of alkaline phosphatase-conjugated streptavidin 
(SA-ALP) was added in the wells (diluted 1/20,000 in 6% 
BSA) and incubated for 15 min. After 6 times final wash-
ing, 100 μL of Diflunisal phosphate (DFP) diluted in sub-
strate buffer, were added to each well and incubated for 
10 min. 100 μL of developing solution were added, mixed 
for 1  min and the fluorescence was measured with the 
Wallac EnVision 2103 Multilabel Reader (Perkin Elmer, 
Waltham, MA, USA).
Hybrid immunoassays using antibodies against KLK9 
and common serine protease inhibitors
Microtiter plates were coated with 28ED436 anti-KLK9 
antibody (500 ng) diluted in 50 mM Tris buffer (pH 7.8) 
and incubated overnight. On the following day, plates 
were washed 3 times and 100 µL of tissue extracts/fluids 
diluted in Buffer B (60 g/L BSA, 25 mL/L normal mouse 
serum, 100  mL/L normal goat serum, 10  g/L bovine 
IgG, 0.005% (v/v) Tween-20 in 50  mM Tris, pH 7.8, 
0.5 M KCl) were added in each well, in a total of 4 dupli-
cates, and incubated at RT (2  h). Subsequently, plates 
were washed 3 times and 100 µL of polyclonal antibod-
ies against different serine protease inhibitors [αlpha-
1-antitrypsin pAb (biot)(A1AT), antithrombin III pAb 
(biot)(ATBIII), a1-antichymotrypsin (serpinA3 rabbit 
Ab), alpha-2-antiplasmin Ab (A2AP) (Fitzgerald, Acton, 
MA, USA), prepared in Buffer B, were added to the 
plates. Additionally, an equal amount of the biotinylated 
anti-KLK9 antibody 4ED28.2 was added in additional 
identical wells as a control. After 1  h incubation, plates 
were washed 3 times. Due to limitations in the available 
detection Abs, we followed both fluorogenic and col-
orimetric detection procedures. In more detail, for the 3 
biotinylated Abs (4ED28.2, anti-AIAT and anti-ATBIII) 
100  μL of alkaline phosphatase-conjugated streptavidin 
(SA-ALP) prepared in 6% BSA was added in each white 
well and incubated for 15 min. Additionally, for the rabbit 
anti-SERPINA3 Ab, 100  µL of the ALP-conjugated goat 
anti-rabbit IgG, diluted in Buffer B, were added in clear 
wells and incubated for 30 min at RT. Then, plates were 
washed 6 times and 100 μL of Diflunisal phosphate (DFP) 
solution, prepared in substrate buffer described above, 
were added into the plate (100 μL per well) and incubated 
for 10 min at RT with gentle shaking. Subsequently, the 
developing solution described above, was added on top 
and mixed for 1  min. Time-resolved fluorescence was 
measured with the Wallac EnVision 2103 Multilabel 
Reader (Perkin Elmer).
In the case of A2AP, 100  μL of HRP-conjugated goat 
anti-mouse IgG (Fc Fraction; Jackson ImmunoResearch) 
(in 1% milk/PBST), were added to each clear well. Follow-
ing a final wash (3 times), 100 μL of 3,3,5,5′-tetramethylb-
enzidine substrate solution were added and plates were 
incubated for 15 min at 37 °C with gentle shaking. 50 μL 
of stop solution (2 M H2SO4) were added on top. Absorb-
ance was measured with the Wallac EnVision 2103 Mul-
tilabel Reader (Perkin Elmer, Waltham, MA, USA) at 
450 nm, with a reference wavelength of 540 nm.
Biological fluids and tissue extracts
Our protocols for the analysis of human tissues and fluids 
have been approved by the Ethics Committee of Mount 
Sinai Hospital, Toronto, Canada. The following human 
tissues (fetal and adult) were used from different individ-
uals; post-mortem. Lung, liver, kidney, heart, fat, uterus, 
pituitary, bone marrow, esophagus, colon, aorta, trachea, 
prostate, thymus, tonsil, pancreas, salivary gland, skin, 
stomach, small intestine, larynx, thyroid, breast, gall-
bladder. Tissue cytosolic extracts were prepared from 
snap-frozen tissues as described elsewhere [15, 16]. The 
supernatants representing the tissue extracts were col-
lected and stored at −80 °C until use. The biological flu-
ids used were: amniotic fluid of 18 weeks gestation, sweat 
(collected after strenuous exercise), breast milk, ascites 
from ovarian cancer, and synovial fluid. Fluids were 
stored at −20 °C until use.
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Fractionation of biological samples by size exclusion 
chromatography
One normal tonsil cytosolic extract and one ascites fluid 
sample, obtained from an ovarian cancer patient, were 
loaded through a 500 µL loop on a silica-based TSKGEL 
G3000SW gel filtration column (60  cm  ×  7.5  mm ID), 
connected to an Agilent 1100 series HPLC system. The 
tonsil extract was diluted 2 times in a buffer containing 
0.1  M NaH2PO4 and 0.1  M Na2SO4 (pH 6.8), while the 
ascites sample was diluted 10 times in the same buffer. 
Separation was accomplished during a 60  min run at a 
flow-rate of 0.5  mL/min. 1  mL fractions were collected 
throughout the run and were analyzed for the presence 
of free and ACT-bound KLK9 isoforms by ELISA, as 
described above.
Results
Mat‑KLK9 protein production, purification and mass 
spectrometric analysis
Mat-KLK9 expression after enhancer induction was 
verified by Western blot analysis using an anti-KLK9 
mouse monoclonal antibody that was previously pro-
duced in-house. SRM analysis using a heavy-labeled pep-
tide for protein quantification (Additional file  1: Table 
S1) showed that the Expi293-KLK9 cells reached a pro-
tein yield of ~10–11  mg/L, 96  h post-transfection. As 
depicted in Fig. 1, the expressed protein migrated around 
~42 kDa, corresponding to the glycosylated KLK9 form. 
Upon deglycosylation by the PNGase F, the 42 kDa band 
migrated at ~25 kDa (data not shown). Large scale KLK9 
expression and collection of the supernatant 96  h post-
transfection, was then performed, to purify the produced 
mat-KLK9 (aa 23–250). The recombinant mat-KLK9 was 
purified using 2 steps: anion-exchange chromatography, 
followed by reversed-phase chromatography. The purity 
was assessed by Coomassie and silver staining SDS-
PAGE (Fig.  1a). The identification and quantification of 
KLK9 in the different chromatographic fractions was 
confirmed by SRM analysis.
Production of mouse mAbs and screening 
against mat‑KLK9 using immunocapture‑PRM
Purified mat-KLK9 was injected into mice for the pro-
duction of monoclonal antibodies by somatic cell fusion 
of murine splenocytes with murine myeloma cells. Eight-
een hybridomas were positive after the initial round 
of screening and were further expanded in serum-free 
media. Purified IgGs were tested against mat-KLK9 
protein by an immunocapture-PRM assay, according 
to which the 28ED436 mAb exhibited the highest bind-
ing signal for the antigen (Additional file 2: Figure S1A). 
We also tested 16 additional mouse monoclonal anti-
bodies, generated by a previous in-house immunization 
and fusion by using a mammalian pro-KLK9 form [17] 
(Additional file 2: Figure S1B). Two mAbs (4ED28.2 and 
MIGI EII), showed high reactivity against mat-KLK9, but 
still, the newly produced 28ED436 antibody showed the 
highest KLK9 binding signal (Additional file  2: Figure 
S1B). Repeatability of the immuno-PRM method and sys-
tem stability were assessed for all monoclonal antibodies 
tested. Each sample was analyzed in duplicates and the 
variation of light/heavy peptide ratio was estimated <13% 
for antibodies of higher binding affinity (e.g. 4ED28.2: 
CV = 12%; 28ED436: CV = 6%). Additionally, the varia-
tion of the spiked heavy peptides’ total ion current across 
all samples was estimated <20%.
Development of KLK9 ELISA
The three aforementioned mAbs were tested in a mono–
mono ELISA assay format against two different recom-
binant KLK9 forms, the mature KLK9 (mat-KLK9) 
(purified here) and a commercially available mamma-
lian pro-KLK9 (R&D Systems, Minneapolis, MN, USA). 
According to these results (Additional file 3: Figure S2), 
28ED436 was chosen as the capture Ab and 4ED28.2 as 
the biotinylated detection antibody.
We tested this assay against the rest of the kallikreins 
(KLK1–KLK15), to exclude the possibility of cross-
reaction. None of the other kallikreins showed meas-
urable readings, even at concentrations of 1  mg/L 
(cross-reactivity: <0.05%). Next, the limit of blank 
(LOB) was estimated at 10 pg/mL (matrix was 6% BSA) 
and the limit of detection (LOD) was around 15 pg/mL 
(LOD  =  LOB  +  1.64  *  SD). Linearity was assessed by 
diluting mat-KLK9 in BSA and the assay was linear in 
the range 0.023–6 ng/mL with each point displaying ade-
quate accuracy (Additional file  4: Figure S3A). Within-
run (N  =  10) and between-run (N  =  10) imprecision 
was assessed over one and 7 different days, respectively. 
Within-run imprecision was <12% and between-run 
imprecision was <21% within the measurement range 
(Additional file  5: Table S4). The limit of quantification 
(LOQ) was equal to the KLK9 concentration with ≤15% 
CV (20 pg/mL). The stability of native KLK9 in sweat, as 
well as the recombinant protein’s (mat-KLK9) stability 
spiked in serum (5 ng/mL), were determined in a 7-day 
(d) experiment (d0  →  d1  →  d7), during which sam-
ple aliquots were stored at 4  °C, RT and −20  °C (Addi-
tional file  4: Figure S3B). KLK9 concentration in sweat 
was stable after 24 h in all cases. On day seven, the KLK9 
concentration decreased at RT only, by about 40% (Addi-
tional file  4: Figure S3B). KLK9 concentration spiked 
in serum decreased by about 60% after 24  h incubation 
(d1) at all conditions and remained relatively stable at 
7  days (Additional file  4: Figure S3C). The KLK9 rapid 
decrease in serum may be attributed to the formation 
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of heterocomplexes between the added mat- KLK9 and 
endogenous serum serine protease inhibitors. This is 
supported by additional data of spiking recombinant 
KLK9 proteins in serum samples obtained from female 
and male individuals. The mat- and pro-KLK9 forms 
were spiked in serum samples (at final concentrations 
of 5 and 10 μg/L) and incubated for 1 h at RT. Recovery 
for mat-KLK9 ranged between 20 and 25%, while pro-
KLK9 recovery was around 90–100% (Additional files 6, 
7: Tables S2,3).
To further evaluate the low recovery of KLK9 in our 
assay and validate the hypothesis that mat-KLK9 could 
form heterocomplexes with the anti-chymotrypsin ser-
pinA3 inhibitor, we spiked different amounts of the 
human recombinant serpinA3 inhibitor into a given 
constant concentration of mat-KLK9 and measured the 
KLK9 free monomer. A gradual decrease in the measured 
KLK9 concentrations was observed along with increasing 
amounts of spiked serpinA3 (Additional file 9: Figure S5), 
clearly indicating the interference of this spiked inhibitor 
with the free KLK9 ELISA.
Detection of KLK9 in tissue samples and biological fluids
Using the newly developed ELISA, KLK9 protein pres-
ence was examined in various human tissue extracts 
(Fig.  2). In general, KLK9 ELISA signal appeared to be 
low in all extracts, suggesting that KLK9 might not be 
synthesized in abundance. Higher KLK9 levels were 
observed in adult tissues, compared to the fetal ones, 
































































Fig. 1 Experimental outline. a Mammalian Expi293F cells were transfected with a pCDNA3.4-KLK9 plasmid and used to produce mat-KLK9. 
Recombinant mat-KLK9 was purified with a 2-step chromatographic separation (anion-exchange followed by reverse-phase chromatography). KLK9 
purity was assessed by silver staining (left panel) and western blot; the major KLK9 band is around 42 kDa. b Mice were immunized for production of 
anti-KLK9 monoclonal antibodies. c An immunocapture-PRM assay was utilized for the optimal selection of high affinity anti-KLK9 mAbs. d Purified 
monoclonal antibodies were used in pairs for the development of a sandwich type ELISA. PRM, Parallel reaction monitoring
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(Fig.  2a). Among the examined biological fluids, KLK9 
was detected in 2/10 sweat samples, whereas the rest of 
the fluids demonstrated low signal (Fig. 2b).
Detection of free and bound forms of KLK9 in biological 
samples
Based on our observation that mat-KLK9 had poor 
recovery in human serum, we sought for evidence that 
both free and bound forms of KLK9 exist in biologi-
cal samples, similar to PSA and other proteinases. We 
set-up hybrid immunoassays in a mono-poly format, 
by using the anti-KLK9 mouse mAb 28ED436 for cap-
ture and commercially available polyclonal antibodies 
against several common serine protease inhibitors [such 
as α1-antitrypsin (A1AT), α1-antichymotrypsin (ACT), 
antithrombin III (ATBIII), and α2-antiplasmin (A2AP)]. 
We tested two KLK9-positive sweat samples (sweat 
samples 14 and 15; Fig. 2b). The ELISA assay signals are 
shown in Additional file  8: Figure S4. Elevated signal in 
the two sweat samples was seen with the KLK9 ELISA 
but not with any of the 4 hybrid assays. In ovarian cancer 
ascites, the major form was KLK9 bound to a1-antichy-
motrypsin (see also below).
Detection of free and bound forms of KLK9 in fractionated 
biological samples
Two samples with detectable KLK9 (tonsil extract 










































































































































































































Fig. 2 KLK9 detection in fetal and adult tissue extracts (a) and biological fluids (b) by the newly developed KLK9 ELISA. The presence of KLK9 pro-
tein was investigated in fetal (upper panel) and adult (lower panel) cytosolic tissue extracts(a), as well as in biological fluids obtained from female and 
male subjects (b). KLK9 measurements are depicted in KLK9 concentration (ng/mL). KLK9 was detected in tonsil, liver, kidney and heart and in 2/10 
sweat samples. For discussion see text
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chromatography and fractions analyzed with two immu-
noassays (KLK9 ELISA and KLK9-ACT hybrid assay). 
For tonsil, KLK9 ELISA had maximum signal at 41 min 
elution time, corresponding to a molecular mass around 
40 kDa (Fig. 3a). The KLK9-ACT ELISA gave no detect-
able signal in any of the fractions. For ascites fluid, KLK9 
ELISA gave no signal, while maximum signal with the 
KLK9-ACT hybrid ELISA assay was seen at 31 min (cor-
responding to a molecular mass of ~100 kDa) (Fig.  3b). 
These data suggest that some biological fluids (tis-
sue extracts, sweat) have predominantly free KLK9 
(~40  kDa) while others (ascites) contain predominantly 
KLK9 bound to a1-antichymotrypsin.
Discussion
Human kallikrein 9 (KLK9) is a serine protease and a 
member of the kallikrein family. Its physiological and 
pathophysiological roles have not as yet been elucidated. 
Some recent data suggest that KLK9 may play an impor-
tant biological role. In brief, KLK9 gene expression was 
found to have favorable prognostic value in ovarian and 
breast cancer [6, 7], while elevated KLK9 expression lev-
els were associated with higher grade gliomas [8]. KLK9 
gene expression has also been related to non-malignant 
diseases. Recent studies associate KLK9 expression 
patterns with cardiac hypertrophy and hypertension-
induced target organ damage [10], psoriatic lesions [11] 
and complications in asthma patients [12]. In general, 
KLK9-related studies are still very few.
We previously produced KLK9 recombinant protein 
and anti-KLK9 monoclonal and polyclonal antibodies 
[17], which were used to develop an ELISA (mono-poly 
format), applied for screening a variety of biological sam-
ples [18]. However, due to the assay’s poor sensitivity, 
there was still a need for improved analytical tools.
Here, mature, enzymatically active mat-KLK9 was pro-
duced in mammalian cells. The purified polypeptide was 
used for the production of new mouse monoclonal anti-
bodies (Fig. 1). It has been previously shown that immu-
noaffinity and mass spectrometric methodologies can 
be combined for the effective screening of hybridoma 
supernatants against the native forms of antigens [14] or 
for elucidation of antigens bound to mAbs of unknown 
specificity [19]. In the present study, we utilized a mass 
spectrometer (Q-Exactive Plus) to design PRM experi-
ments (Additional file 2: Figure S1) and rapidly screen the 
monoclonal antibodies [14, 19, 20]. A potential limita-
tion of the current protocol is perhaps the inaccuracy of 
antigen quantification in some cases. In more detail, the 
structure of the formatted immunocomplex could cause 
incomplete trypsin digestion, due to occlusion of cleav-
age sites, and thus in inadequate MS analysis. Therefore, 
one should consider applying more stringent sample prep 
conditions, such as heating above 60 °C during the initial 
reduction step, or even adding an extra denaturing factor 
(e.g. Rapigest).
A newly produced mAb (28ED436) and a pre-existing 
one (4ED28.2) were paired to develop a sandwich-type 
ELISA (Additional file 3: Figure S2). The assay was highly 
sensitive (LOD: 15  pg/mL), thus meeting the demands 
for future clinical studies [21], as well as highly specific 
(cross-reactivity with all other KLKs: <0.05%). The esti-
mated recovery of mat-KLK9 from human serum was 
low (~20–25%), whereas pro-KLK9 recovery was much 
higher (90–100%), suggesting a possible interaction of 
the active KLK9 enzyme with endogenous inhibitors 
(Additional files 6, 7: Table S2, 3). This speculation was 
670 kDa 158 kDa 44 kDa 17 kDa 1.3 kDa
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Fig. 3 Size exclusion chromatographic separation of a tonsil tissue 
extract and b ovarian cancer ascites. Samples were fractionated and 
the collected fractions were analyzed by ELISA using the following 
antibody pairs: a mouse mAbs 28ED436 and 4ED28.2; b mouse mAb 
28ED436 and rabbit pAb anti-serpinA3. The corresponding molecular 
mass of each peak was estimated according to molecular mass stand-
ards, eluting as indicated by arrows on top panel. In tonsil, the major 
form is free KLK9, eluting at a molecular mass of ~35 kDa. In ascites, 
the major form is KLK9 bound to a1-antichymotrypsin (KLK9-ACT), 
eluting around 100 kDa. For more discussion see text
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strengthened by the observation that the titration of the 
serpinA3 inhibitor in mat-KLK9 solution interfere with 
the free KLK9 ELISA (Additional file 9: Figure S5).
Screening of human tissue samples revealed higher 
KLK9 levels in adult tissues compared to the fetal ones, 
predominantly in tonsil extracts and at lower levels in 
kidney, liver and heart (Fig.  2a). These findings are in 
good agreement with RNA expression data (http://www.
proteinatlas.org/). Only two out of 10 sweat samples were 
moderately positive for KLK9 among the tested biologi-
cal fluids (Fig. 2b). KLK9 signal was very low in the sera 
of healthy females and males, in accordance with previ-
ous studies [16]. In light of the recovery experiments, we 
speculated that these findings could point to a significant 
binding of KLK9 by endogenous serum inhibitors [22–
24]. The formation of these heterocomplexes [25] could 
effectively mask KLK9 epitopes. This has been observed 
with many other kallikreins, including PSA [24, 26, 27].
We set up hybrid assays using one capture Ab 
(28ED436) and polyclonal Abs targeting the most com-
mon serine protease inhibitors, such as A1AT, serpinA3, 
ATBIII and A2AP. The KLK9–serpinA3 Ab combina-
tion gave the highest signal, compared to the rest of the 
inhibitors. This was not surprising, given that KLK9 is 
predicted to be a chymotryptic enzyme [28]. Further 
screening of biological tissues and fluids, suggests that 
in some samples KLK9 is mostly present in its bound to 
ACT form (e.g. ascites) while in others (e.g. sweat) it is a 
free monomer. To strengthen our hypothesis, we sought 
for free and bound KLK9 forms in two biological sam-
ples (i.e. a tonsil homogenate and ascites fluid) which 
had been fractionated by size exclusion chromatography 
(Fig. 3). The results are suggestive of two distinct forms 
for KLK9 in each sample. In tonsil homogenate, which 
was only positive with the KLK9 assay, there is only one 
peak, appearing at ~40  kDa (Fig.  3a). In ovarian cancer 
ascites, that was positive only with the hybrid assay, there 
is only one 100 kDa form (Fig. 3b).
These data suggest that KLK9, like other kallikreins 
[29, 30] exists as a free active protease in tissues or flu-
ids devoid of inhibitors (e.g. tonsil and sweat) or repre-
sents a pro-enzyme or an inactivated proteolytic form 
[31, 32]. Active KLK9 (mat-KLK9) also interacts with 
endogenous protease inhibitors in biological samples and 
more specifically, with a1-antichymotrypsin (ACT). In a 
similar manner, a1-antichymotrypsin binds to other chy-
motrypsin-like kallikreins, such as PSA and/or KLK7, in 
serum [31, 33]. Since the free/total PSA ratio in serum of 
prostate cancer patients is used for diagnostic and prog-
nostic purposes [26], this could suggest a similar applica-
tion of KLK9.
In summary, our newly developed tools for quantify-
ing free and ACT-bound KLK9 with high sensitivity and 
specificity will facilitate further studies aiming to better 
define the role of KLK9 in health and disease.
Conclusions
The development of ELISAs for the accurate quantifica-
tion of the free and bound to a1-antichymotrypsin KLK9 
forms will be a valuable tool for the quantification of 
KLK9 in a broad range of biological samples in normal 
and diseased individuals. Our newly developed tools for 
quantifying free and ACT-bound KLK9 with high sensi-
tivity and specificity will facilitate further studies aiming 
to better define the role of KLK9 in health and disease.
Additional files
Additional file 1: Table S1. SRM assay parameters for KLK9 analysis.
Additional file 2: Figure S1. Screening for KLK9 monoclonal antibodies 
by immunocapture-PRM. (A) Microtiter plates were coated with equal 
amounts of purified mAbs and incubated with 50 ng of mat-KLK9. Follow-
ing Ag capture, the proteins in the wells were trypsin-digested and pep-
tides were analyzed by a PRM assay. Results are depicted as KLK9 peptide 
intensity ratios (Light-to-Heavy, L/H) with bars representing the respective 
standard error. (B) Comparison of signals between the newly produced 
mAb 28ED436 and 16 previously developed mAbs against mat-KLK9. 
Trypsin digestion and PRM analysis were performed as in panel A. The 
three highest affinity antibodies were used for KLK9 ELISA development.
Additional file 3: Figure S2. Testing mouse anti-KLK9 mAbs for optimal 
pairing against KLK9. Standard sandwich ELISAs were developed using the 
following combinations: (i) 28ED436 vs. biotinylated 4ED28.2 and MIGI EII, 
(ii) 4ED28.2 vs. biotinylated 28ED436 and MIGI EII, and (iii) MIGI EII vs. bioti-
nylated 28ED436 and 4ED28.2. The mat-KLK9 and the pro-form of KLK9 
(R&D systems) (final concentrations: 2.5 and 5 μg/L) were used as antigens. 
The best signal was obtained with the pair 28ED436 (coating)-4ED28.2 
(biotinylated; detection). For more details see text. 1. pro-KLK9 (5 μg/L), 2. 
pro-KLK9 (2.5 μg/L), 3. mat-KLK9 (5 μg/L), 4. mat-KLK9 (2.5 μg/L).
Additional file 4: Figure S3. Linearity and stability of the KLK9 
immunoassay. (A) The linearity of KLK9 ELISA was assessed by diluting 
recombinant KLK9 in BSA. Serial dilutions of the samples were prepared 
and the assay was performed by following the described protocol. 
Linear correlation was estimated between the theoretically spiked KLK9 
concentrations and the ELISA-estimated KLK9 concentrations (regression 
coefficient β1 = 1.20, P < 0.0001). Sample stability was tested through a 
7-day experiment, by storing sweat samples (B), as well as serum samples 
with spiked mat-KLK9 (C) at room temperature (RT), 4 °C and −20 °C. 
KLK9 was measured at 3 points (Days 0, 1 and 7) by the ELISA assay. For 
comments see text.
Additional file 5: Table S4. ELISA within-run and total imprecision.
Additional file 6: Table S2. Recovery of recombinant mat-KLK9 spiked in 
female (F) and male (M) serum samples.
Additional file 7: Table S3. Recovery of recombinant pro-KLK9 spiked in 
female (F) and male (M) serum samples.
Additional file 8: Figure S4. Development of hybrid ELISAs for the 
detection of KLK9 heterocomplexes with serine protease inhibitors. 
In-house generated mAb 28ED436 was used as capture Ab, while pAbs 
against common serine protease inhibitors (e.g. A1AT, ACT, ATBIII, and 
A2AP) were used as secondary Abs in two biological fluids (sweat 14 
and 15). The A2AP (HRP-conjugated) levels were undetectable and are 
not shown in the graph. KLK9 measurements were depicted as arbitrary 
fluorescence units. The ELISAs used include the first antibody as coating 
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